Journals / Akdeniz Tıp Dergisi / 2015 / Cilt: 1 - Sayı: 3

Radiotherapy in Gynecological Cancers: Analysis of Treatment Results and Prognostic Factors

Radyoterapi Uygulanan Jinekolojik Tümör Tanılı Olgularda Radyoterapi Uygulanan Jinekolojik Tümör Tanılı Olgularda Tedavi Sonuçları ve Prognostik Faktörler Tedavi Sonuçları ve Prognostik Faktörler

Pages
142–149
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The median overall survivals were 26.3 and 21.1 months for patients with endometrial and cervical cancer respectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To evaluate the patients with gynecologic tumors undergoing radiotherapy.
📊
Key Findings & Data:Material and Methods: Seventy-eight patients with a diagnosis of gynecological malignancy who received curative radiotherapy (RT) between June 2010-January 2013 were retrospectively evaluated.
💡
Conclusion & Impact:The median overall survivals were 26.3 and 21.1 months for patients with endometrial and cervical cancer respectively.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: To evaluate the patients with gynecologic tumors undergoing radiotherapy. Material and Methods: Seventy-eight patients with a diagnosis of gynecological malignancy who received curative radiotherapy (RT) between June 2010-January 2013 were retrospectively evaluated. Results: We treated 33, 44 and 1 patient for cervical cancer, endometrial cancer and endocervical canal tumor respectively. The median age was 56 years (34-83). The mean follow-up period was 23.9±1.4 months. At the time of diagnosis, 18 (23.1%) patients were premenopausal whereas 60 (74.9%) patients were postmenopausal. Thirty-one endometrial cancer patients received adjuvant RT while 9 received adjuvant chemotherapy and RT. Five of the patients with a diagnosis of recurrent endometrial cancer received RT after salvage surgery. Sixteen patients with locally advanced cervical cancer were treated with defi nitive chemoradiotherapy. Ten patients (30.3%) who were operated on for cervical cancer were administered adjuvant RT whereas 6 patients (18.2%) received adjuvant chemoradiotherapy. The patient with endocervical canal tumor received adjuvant chemoradiotherapy. The median overall survivals were 26.3 and 21.1 months for patients with endometrial and cervical cancer respectively. Cox-regression analyses revealed that there was a relationship between the overallsurvival and local recurrence (p=0.046), tumor diameter (p= 0.030) and stage (p= 0.036); on the other hand there was no relationship between the overall survival and lymphovascular invasion (p=0.711) and myometrial invasion (p=0.684). Conclusion: Survival in endometrial cancer is associated with local recurrence, maximal tumor diameter and stage. For cervical cancer, there is a close association with lymph node involvement and disease-free survival.

Özet

Amaç: Radyoterapi tedavisi alan jinekolojik tümörlü hastaların değerlendirilmesi. Gereç ve Yöntemler: Haziran 2010-Ocak 2013 tarihleri arasında küratif radyoterapi (RT) uygulanan 78 jinekolojik tümörlü hasta retrospektif olarak değerlendirildi. Bulgular: Olguların 33'ü serviks kanseri, 44'ü endometriyum kanseri ve 1'i endoservikal kanal tü- mörü nedeni ile tedavi edildi. Medyan yaşı 56 idi (aralık: 34-83 ). Ortalama izlem süresi 23,9±1,4 ay idi. Tanı anında 18 hasta (%23,1) premenopozal, 60 hasta (%74,9) postmenopozaldi. Endometriyum kanseri nedeni ile opere edilen olguların 31'i adjuvan RT alırken; 9 olgu postoperatif KT ve RT aldı. Endometriyum kanseri tanısı olan 5 hasta nüks nedeni ile kurtarma cerrahisi ardından RT aldı. Serviks kanseri nedeni ile RT uygulanan hastaların 16'sına lokal ileri evre serviks kanseri nedeni ile defi nitif kemoradyoterapi uygulandı. On (%30,3) serviks kanseri tanılı olgu ise adjuvan RT; 6 hasta (%18,2) adjuvan kemoradyoterapi (KRT), 1 olgu ise (%3) kurtarma amaçlı RT aldı. Endoservikal kanal tümörü tanısı olan hastaya adjuvan KRT uygulandı. Endometriyum kanseri nedeni ile RT uygulanan hastalarda medyan sağkalım 26,3 ay, serviks kanseri nedeni ile RT uygulanan hastalarda ise 21,1 ay olarak bulundu. Endometriyum kanseri tanısı ile tedavi edilen hastalarda cox-regresyon analizinde lokal nüks (p=0,046) , tümör çapı (p= 0,030) ve evrenin (p= 0,036) sağkalım ile ilişkisi gösterilirken; lenfovasküler alan invazyonu (p=0,711), myometriyal invazyonun (p=0,684) sağkalım ile ilişkisi gösterilememiştir. Serviks kanseri nedeni ile tedavi edilen hastalarda ise lenf nodu pozitifl iği ile progresyonsuz hastalık arasında ilişki gösterilmiştir (p=0,043). Sonuç: Endometriyum kanserinde lokal nüks , tümör çapı ve evre sağkalım ile ilişkilidir. Serviks kanserinde ise lenf nodu pozitifl iği ile progresyonsuz hastalık arasında ilişki mevcuttur.

🔖

Cite This Article

DOĞAN, N. U., ÇELİK, Ç., YAVAŞ, G., YAVAŞ, Ç. (2022). Radiotherapy in Gynecological Cancers: Analysis of Treatment Results and Prognostic Factors. Akdeniz Tıp Dergisi, Cilt: 1 - Sayı: 3, 142–149. https://ajindex.com/articles/434546

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65(2):87-108.
  2. Anton C, Fávero GM, Köhler C, Carvalho FM, Baracat EC, Carvalho JP. Surgical treatment of endometrial cancer in developing countries: Reasons to consider systematic two-step surgical treatment. Clinics (Sao Paulo) 2015;70(7):470-4. Kanserle Savaş Dairesi Başkanlığı verileri. www.kanser. gov.tr Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. Cancer J Clin 2007; 57:43-66.
  3. Alvarez Secord A, Havrilesky LJ, Bae-Jump V. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol 2007;107: 285-91.
  4. Dogan NU, Yavas G, Yavas C, Ata O, Yılmaz SA, Celik C. Comparison of "sandwich chemo-radiotherapy" and six cycles of chemotherapy followed by adjuvant radiotherapy in patients with stage IIIC endometrial cancer: A single center experience. Arch Gynecol Obstet 2013;288(4):845-5.
  5. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma; A gynecologic oncology group study. Gynecol Oncol 2004;92:744-51. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-I endometrial carcinoma: Multicentre randomized trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet 2000;55:1404-11.
  6. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Eng J Med 1999;340:1137-43.
  7. Whitney CW, Sause W, Bundy BN et al. Randomized comparison of fl hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para- aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-48.
  8. Eifel PJ, Moughan J, Owen J et al. Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: Patterns of Care Study. Int J Radiat Oncol Biol Phys 1999;43:351-8.
  9. Rose PG, Bundy BN, Watkins EB. Concurrent cisplatin- based chemotherapy and radiotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340:1144- 53. Nag S, Erickson B, Thomadsen B, Orton C, Demanes JD, Petereit D. The Americ